INVO Bioscience, Inc. (INVO)
NASDAQ: INVO · Real-Time Price · USD
0.700
+0.025 (3.70%)
At close: Oct 4, 2024, 4:00 PM
0.720
+0.020 (2.86%)
After-hours: Oct 4, 2024, 5:28 PM EDT
INVO Bioscience Employees
As of December 31, 2023, INVO Bioscience had 30 total employees, including 25 full-time and 5 part-time employees. The number of employees increased by 14 or 87.50% compared to the previous year.
Employees
30
Change (1Y)
14
Growth (1Y)
87.50%
Revenue / Employee
$192,318
Profits / Employee
-$236,164
Market Cap
2.73M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Tonix Pharmaceuticals Holding | 103 |
| Nuwellis | 59 |
| TC Biopharm (Holdings) | 41 |
| Scinai Immunotherapeutics | 31 |
| ReShape Lifesciences | 29 |
| Phio Pharmaceuticals | 9 |
| Shuttle Pharmaceuticals Holdings | 8 |
| Ensysce Biosciences | 7 |
INVO News
- 5 months ago - INVO Reports Record First Quarter 2024 Financial Results - GlobeNewsWire
- 6 months ago - INVO Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 10 months ago - NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal - PRNewsWire
- 10 months ago - NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies - PRNewsWire
- 11 months ago - INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement - PRNewsWire
- 11 months ago - INVO Reports Record Third Quarter 2023 Financial Results - PRNewsWire
- 11 months ago - NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger - PRNewsWire
- 11 months ago - INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants - PRNewsWire